Antiproteinuric effect of KD3-671, an angiotensin II type 1 receptor antagonist, in rats with accelerated passive Heymann nephritis.

Abstract

The antiproteinuric effect of KD3-671 (2-propyl-8-oxo-1-[(2'-(H-tetrazole-5-yl)biphenyl-4-yl)methyl]-4,5,6,7-tetrahydrocycloheptimidazole), an angiotensin II type 1 receptor antagonist, was compared with that of enalapril, an angiotensin 11-converting enzyme inhibitor, using an experimental model of membranous nephropathy. KD3-671 (3, 10 and 30 mg/kg per day) and enalapril (30 mg/kg per day) were given p.o. for 40 days, respectively. KD3-671 (30 mg/kg per day) inhibited the elevation of proteinuria and plasma total cholesterol. On the other hand, enalapril showed only a tendency to diminish these parameters. KD3-671 had an antiproteinuric effect in rats with accelerated passive Heymann nephritis. These findings provide considerable encouragement for the clinical development of KD3-671.

• Authors: Tadashi Nagamatsu, Toshiyuki Nagao, Kazumi Hayashi, Yoshio Suzuki
• Journal: Japanese journal of pharmacology (Jpn J Pharmacol) Vol. 88 Issue 2 Pg. 213-6 (Feb 2002) ISSN: 0021-5198 [Print] Japan
• PMID: 11928723 (Publication Type: Comparative Study, Journal Article)

Chemical References

• Angiotensin Receptor Antagonists
• Angiotensin-Converting Enzyme Inhibitors
• Imidazoles
• KD3 671
• Tetrazoles
• Enalapril
• Cholesterol

Topics

• Angiotensin Receptor Antagonists
• Angiotensin-Converting Enzyme Inhibitors (blood, therapeutic use)
• Animals
• Blood Urea Nitrogen
• Cholesterol (blood)
• Enalapril (blood, therapeutic use)
• Glomerulonephritis (drug therapy)
• Imidazoles (blood, chemistry, therapeutic use)
• Male
• Proteinuria (drug therapy)
• Rats
• Rats, Sprague-Dawley
• Tetrazoles (blood, chemistry, therapeutic use)